Related Experiment Videos
[Clinical evaluation of a new oral cephem, cefpodoxime proxetil in children]
H Meguro1, O Arimasu, H Shiraishi
1Department of Pediatrics, School of Medicine, Teikyo University.
Insights
Cefpodoxime proxetil (CPDX-PR) demonstrated high efficacy (93.6%) and safety in treating pediatric infections. Dosing twice or thrice daily proved sufficient for common bacterial infections in children.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Clinical Microbiology
Abstract:
Cefpodoxime proxetil (CPDX-PR, CS-807) was evaluated for its efficacy, safety and pharmacokinetics in children. CPDX-PR was effective in 93.6% of 47 cases with respiratory tract, middle ear, skin or urinary tract infections. Twice or 3 times daily administration of 3 mg/kg each was sufficient to treat streptococcal pharyngitis and Haemophilus influenzae infections. No severe adverse reaction was encountered in 52 cases treated with CPDX-PR. The serum half-life was approximately 2.17 +/- 0.24 hours after oral administration.